Insights on implementing digital breast tomosynthesis from someone who knows

Huge Two-Day Clean Sweep Auction July 24-25th. Click Here to Bid!

Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Women's Health Homepage

Study advises personalized breast cancer screenings for cancer survivors May benefit from MR alone, rather than MR and mammography

Genetics and the future of breast cancer assessment Insights from Pam Cumming, senior director of women’s health for Siemens Healthineers North America

The road ahead for breast density awareness It's been a good year for advocacy, here's what happens next

Global breast ultrasound market expected to reach $1.7 billion by 2023 Driven by novel vendor techniques, machine learning and deep-learning algorithms

Understanding the value of molecular breast imaging Delivering personalized care at Mercy Medical Center

OB/GYN ultrasound: is the field ready to adopt new technology in the market? What do new capabilities mean for creatures of habit?

The role of OB/GYNs in delivering personalized breast care Informed care requires an individual approach

Artificial intelligence in next-generation breast cancer detection Purchasing insights from the experts at MD Buyline

Breast imaging advances with new AI, MR and ultrasound solutions A look at innovative new technology entering the market

AI model predicts malignant breast cancer as well as humans: IBM Incorporates mammogram and EHR data in predictions

Dr. Stacy Smith-Foley

Insights on implementing digital breast tomosynthesis from someone who knows

From the July 2019 issue of DOTmed HealthCare Business News magazine

By: Dr. Stacy Smith-Foley

Since its introduction into the market in 2011, digital breast tomosynthesis (DBT) has been gaining support among radiologists as a screening modality that can help detect early and invasive breast cancer.
According to Mammography Quality Standards Act and Program (MQSA) national statistics featured by the Food and Drug Administration (FDA), there are more than 8,600 certified facilities in the United States and approximately 5,200 of them have DBT units.

Story Continues Below Advertisement

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.



Although these statistics indicate that DBT is now considered the gold standard of breast cancer screening, there remains room for improvement to embrace adoption more fully across the country — and that starts with truly embracing the benefits of DBT. As a radiologist who is currently launching my third DBT adoption program at a breast imaging facility, I am uniquely poised to advocate for how DBT can have a positive impact on clinicians and patients.

I experienced my first two DBT modality launches in 2016 at the Breast Center of Northwest Arkansas, and subsequently at the Leta M. Chapman Breast Center in Oklahoma. To implement DBT, my colleagues and I had to develop a consensus on imaging protocols, such as determining which patients would have screening with DBT, and if we would use DBT on diagnostic patients or callbacks. After that, it was fairly easy to adopt the technology.

As anticipated, and as DBT skeptics will argue, using DBT technology did not reduce image reading time. However, I quickly found that its significant advantages far outweighed this challenge. In the first week of offering DBT screening as an option for patients, my colleagues and I diagnosed breast cancer that could only be visualized on the DBT images. In fact, in many cases, we identified cancer in patients who we had been screening for years using standard 2D imaging. It was only with the 3D images that we could see the architectural distortion that had gone undetected for years.

At a time when improving patient outcomes was growing in importance, having the ability to detect more cancer was a crucial point of positive change for us. We were so confident in our DBT screening results that we, in fact, offered a cash price to patients whose insurance did not cover DBT. These patients could still elect the option of “3D mammography,” and they could still benefit from the increased cancer detection and reduced call back rates.

The more comfortable we grew with using DBT, the easier it became to see the distinction between an imaging finding we would have usually called back and where DBT confidently allowed us to skip callback. Perhaps most interesting was that DBT created a paradigm shift in the way we triaged patients.
  Pages: 1 - 2 >>

Women's Health Homepage


You Must Be Logged In To Post A Comment